Topical timolol maleate gel for non-complicated superficial infantile haemangiomas
Phase 1
Completed
- Conditions
- Infantile haemangiomaSkin - Dermatological conditions
- Registration Number
- ACTRN12610001069044
- Lead Sponsor
- Sydney Children's Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
infantile haemangiomas <5 cm
Exclusion Criteria
PHACE syndrome
lesions >5cm diametre
deep subcutaneous lesions
<5 weeks old
>24 weeks old
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie timolol maleate's efficacy in superficial infantile haemangiomas?
How does topical timolol compare to systemic propranolol in treating non-complicated infantile hemangiomas?
Are there specific biomarkers that predict response to beta-blocker therapy in infantile hemangioma patients?
What are the potential adverse events associated with topical timolol gel in pediatric dermatological applications?
What combination therapies are being explored alongside beta-blockers for infantile haemangioma treatment?